Literature DB >> 11051391

Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid.

T Kurihara, A Niimi, A Maeda, M Shigemoto, K Yamashita.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11051391     DOI： 10.1111/j.1572-0241.2000.03220.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  26 in total

1.  Fenofibrate-induced liver injury.

Authors:  Kazufumi Dohmen; Chun Yang Wen; Shinya Nagaoka; Koji Yano; Seigo Abiru; Toshihito Ueki; Atsumasa Komori; Manabu Daikoku; Hiroshi Yatsuhashi; Hiromi Ishibashi
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

Review 2.  Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein).

Authors:  Ronald P J Oude Elferink; Coen C Paulusma
Journal:  Pflugers Arch       Date:  2006-04-19       Impact factor: 3.657

3.  Effect of bezafibrate on hepatic oxidative stress: comparison between conventional experimental doses and clinically-relevant doses in mice.

Authors:  Takero Nakajima; Naoki Tanaka; Gang Li; Rui Hu; Yuji Kamijo; Atsushi Hara; Toshifumi Aoyama
Journal:  Redox Rep       Date:  2010       Impact factor: 4.412

4.  Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis.

Authors:  Cynthia Levy; Keith D. Lindor
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

5.  Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.

Authors:  Runalia Bahar; Kimberly A Wong; Chung H Liu; Christopher L Bowlus
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

6.  Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.

Authors:  Atsushi Tanaka; Junko Hirohara; Yasuni Nakanuma; Hirohito Tsubouchi; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2014-09-20       Impact factor: 7.527

Review 7.  Proposed therapies in primary biliary cholangitis.

Authors:  Annarosa Floreani; Ying Sun; Zheng Sheng Zou; Baosen Li; Nora Cazzagon; Christopher L Bowlus; M Eric Gershwin
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2016-01-06       Impact factor: 3.869

8.  A human hepatocyte-bearing mouse: an animal model to predict drug metabolism and effectiveness in humans.

Authors:  Katsutoshi Yoshizato; Chise Tateno
Journal:  PPAR Res       Date:  2009-10-26       Impact factor: 4.964

9.  Fenofibrate in primary biliary cirrhosis: a pilot study.

Authors:  E N Liberopoulos; M Florentin; M S Elisaf; D P Mikhailidis; E Tsianos
Journal:  Open Cardiovasc Med J       Date:  2010-04-28

Review 10.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.